NFL Biosciences SA (EPA:ALNFL)

Market Cap	8.24M -50.3%
Revenue (ttm)	188.00 +308.7%
Net Income	-3.32M
EPS	-0.26
Shares Out	12.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,781
Open	0.6510
Previous Close	0.6500
Day's Range	0.6400 - 0.6700
52-Week Range	0.6400 - 1.8460
Beta	1.15
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 22, 2026

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 4
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNFL

Financial Performance

In 2025, NFL Biosciences's revenue was 188, an increase of 308.70% compared to the previous year's 46. Losses were -3.32 million, 59.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error